Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety

References

• Olivares JM, Alptekin K, Azorin K, et al. Psychiatrists’ awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa. Patient Prefer Adherence. 2013;7:121–132. doi:10.2147/PPA.S37534
   PubMed Web of Science ®Google Scholar
• Subotnik KL, Nuechterlein KH, Ventura J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011;168(3):286–292. doi:10.1176/appi.ajp.2010.09010087
   PubMed Web of Science ®Google Scholar
• Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–829. doi:10.1001/jamapsychiatry.2015.0270
   PubMed Web of Science ®Google Scholar
• Pungor K, Sanchez P, Pappa S, et al. The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia. BMC Psychiatry. 2021;21:300. doi:10.1186/s12888-021-03305-z
   PubMed Web of Science ®Google Scholar
• Spoelstra SK, Bruins J, Bais L, et al. One-month versus three-month formulation of paliperidone palmitate treatment in psychotic disorders: patients’, relatives’, and mental health professionals’ perspectives. Patient Prefer Adherence. 2022;16:615–624. doi:10.2147/PPA.S349460
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mascarenas C. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64(Suppl 16):18–23.
   PubMed Web of Science ®Google Scholar
• Lamb YN, Keatin GM. Paliperidone palmitate intramuscular 3-monthly formulation: a review in schizophrenia. Drugs. 2016;76:1559–1566. doi:10.1007/s40265-016-0645-5
   PubMed Web of Science ®Google Scholar
• Magnusson MO, Samtani MN, Plan EL, et al. Dosing and switching strategies for paliperidone palmitate 3-month formulation in patients with schizophrenia based on population pharmacokinetic modeling and simulation, and clinical trial data. CNS Drugs. 2017;31:273–288. doi:10.1007/s40263-017-0416-1
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830–839. doi:10.1001/jamapsychiatry.2015.0241
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19(7):pyw018. doi:10.1093/ijnp/pyw018
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kim E, Bermak J, et al. Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidone. J Clin Psychiatry. 2017;78:e813–e820. doi:10.4088/JCP.16m11308
   PubMed Web of Science ®Google Scholar
• García-Carmona JA, Barnett J, Campos-Navarro MP, et al. Comparative effectiveness of long-acting injectable antipsychotics in a large naturalistic cohort across two European centers: findings from the long-acting injectable antipsychotics collaborative (LAICO) study. Neurosci Appl. 2022;1:100111. doi:10.1016/j.nsa.2022.100111
   Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia. JAMA Psychiatry. 2017;74:686–693. doi:10.1001/jamapsychiatry.2017.1322
   PubMed Web of Science ®Google Scholar
• Mathews M, Gopal S, Nuamah I, et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1365–1379. doi:10.2147/NDT.S197225
   PubMed Web of Science ®Google Scholar
• Di Lorenzo R, Iorio A, Pinelli M, et al. Effectiveness and quality of life with paliperidone palmitate 3-monthly in comparison with other long-acting drugs. Neuropsychiatr Dis Treat. 2022;18:829–846. doi:10.2147/NDT.S356341
   PubMed Web of Science ®Google Scholar
• Pappa S, Barnett J, Gomme S, et al. Shared and supported decision making in medication in a mental health setting: how far have we come? Community Ment Health J. 2021;57:1566–1578. doi:10.1007/s10597-021-00780-2
   PubMed Web of Science ®Google Scholar
• Finnerty MT, Layman DM, Chen Q, et al. Use of a web-based shared decision-making program: impact on ongoing treatment engagement and antipsychotic adherence. Psychiatr Serv. 2018;69(12):1215–1221. doi:10.1176/appi.ps.201800130
   PubMed Web of Science ®Google Scholar
• Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–594. doi:10.1056/NEJMoa2108891
   PubMed Web of Science ®Google Scholar
• Office of National Statistics UK. Coronavirus (COVID-19) latest insights. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights. Accessed January 24, 2023.
   Google Scholar
• World Health Organisation. WHO Coronavirus (Covid-19) dashboard. Available from: https://covid19.who.int/. Accessed January 24, 2023.
   Google Scholar
• Cullen W, Gulati G, Kelly BD. Mental health in the COVID-19 pandemic. QJM. 2020;113(5):311–312. doi:10.1093/qjmed/hcaa110
   PubMed Web of Science ®Google Scholar
• Rodgers M, Dalton J, Harden M, et al. Integrated care to address the physical health needs of people with severe mental illness: a mapping review of the recent evidence on barriers, facilitators and evaluations. Int J Integr Care. 2018;18(1):9. doi:10.5334/ijic.2605
   PubMedGoogle Scholar
• Fernández-Miranda JJ, Díaz-Fernández S, De Berardis D, López-Muñoz F. Paliperidone Palmitate Every Three Months (PP3M) 2-year treatment compliance, effectiveness and satisfaction compared with Paliperidone Palmitate-Monthly (PP1M) in people with severe schizophrenia. J Clin Med. 2021;10(7):1408. doi:10.3390/jcm10071408
   PubMed Web of Science ®Google Scholar
• Blackwood C, Sanga P, Nuamah I, et al. Patients’ preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire. Patient Prefer Adherence. 2020;14:1093–1102. doi:10.2147/PPA.S251812
   PubMed Web of Science ®Google Scholar
• Lai JK, Margolese HC. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic. Schizophr Res. 2019;204:443–444. doi:10.1016/j.schres.2018.09.012
   PubMed Web of Science ®Google Scholar
• Garcia-Portilla MP, Llorca PM, Maina G, et al. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. Ther Adv Psychopharmacol. 2020;10:2045125320926347. doi:10.1177/2045125320926347
   Web of Science ®Google Scholar
• Buckley PF, Schooler NR, Goff DC, et al. Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study. Psychiatr Serv. 2016;67(12):1370–1372. doi:10.1176/appi.ps.201500466
   PubMed Web of Science ®Google Scholar
• Pietrini F, Albert U, Ballerini A, et al. The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatr Dis Treat. 2018;15:1045–1060. doi:10.2147/NDT.S199048
   Web of Science ®Google Scholar
• Vauth R, Kleim B, Wirtz M, Corrigan PW. Self-efficacy and empowerment as outcomes of self-stigmatizing and coping in schizophrenia. Psychiatry Res. 2007;150:71–80. doi:10.1016/j.psychres.2006.07.005
   PubMed Web of Science ®Google Scholar
• Wahl OF. Mental health consumers’ experience of stigma. Schizophr Bull. 1999;25:467–478. doi:10.1093/oxfordjournals.schbul.a033394
   PubMed Web of Science ®Google Scholar
• Wright ER, Gronfein WP, Owens TJ. Deinstitutionalization, social rejection, and the self-esteem of former mental patients. J Health Soc Behav. 2000;41:68–90. doi:10.2307/2676361
   PubMed Web of Science ®Google Scholar
• Sibitz I, Unger A, Woppmann A, Zidek T, Amering M. Stigma resistance in patients with schizophrenia. Schizophr Bull. 2011;37(2):316–323. doi:10.1093/schbul/sbp048
   PubMed Web of Science ®Google Scholar
• Lysaker PH, Vohs JL, Tsai J. Negative symptoms and concordant impairments in attention in schizophrenia: associations with social functioning, hope, self-esteem and internalized stigma. Schizophr Res. 2009;110(1–3):165–172. doi:10.1016/j.schres.2009.01.015
   PubMed Web of Science ®Google Scholar
• Yanos PT, Roe D, Markus K, Lysaker PH. Pathways between internalized stigma and outcomes related to recovery in schizophrenia spectrum disorders. Psychiatr Serv. 2015;59:1437–1442. doi:10.1176/ps.2008.59.12.1437
   Google Scholar
• Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(5):1225–1237. doi:10.1093/schbul/sbl071
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. Measuring quality of life in patients with schizophrenia. PharmacoEconomics. 2012;30:183–195. doi:10.2165/11594470-000000000-00000
   PubMed Web of Science ®Google Scholar
• Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bouzoño M. Quality of life in schizophrenic patients. Dialogues Clin Neurosci. 2007;9(2):215–226. doi:10.31887/DCNS.2007.9.2/jbobes
   PubMedGoogle Scholar
• Narvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL. Subjective and objective quality of life in schizophrenia. Schizophr Res. 2008;98(1–3):201–208. doi:10.1016/j.schres.2007.09.001
   PubMed Web of Science ®Google Scholar
• Najarian D, Sanga P, Wang S, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238–251. doi:10.1093/ijnp/pyab071
   PubMed Web of Science ®Google Scholar
• Barnett J, Mason K, Pappa S. The relationship between level of compliance with aripiprazole long-acting injectable and risk of hospitalisation. Eur Neuropsychopharmacol. 2021;53(supp. 1):S354–S355. doi:10.1016/j.euroneuro.2021.10.453
   Google Scholar
• Pappa S, Mason K. Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study. Ther Adv Psychopharmacol. 2020;10:204512532092478. doi:10.1177/2045125320924789
   Web of Science ®Google Scholar
• Seeman M. The pharmacodynamics of antipsychotic drugs in women and men. Front Psychiatry. 2021;12. doi:10.3389/fpsyt.2021.650904
   Web of Science ®Google Scholar
• Pappa S, Barnett J, Mason K. A 10-year observational study of the use, acceptability and effectiveness of long-acting paliperidone palmitate: implications for clinical decision making. CNS Drugs. 2023;37:107–116. doi:10.1007/s40263-022-00976-4
   PubMed Web of Science ®Google Scholar
• Pappa S, Mason K, Howard E. Long-term effects of paliperidone palmitate on hospital stay and treatment continuation. Int Clin Psychopharmacol. 2019;34(6):305–311. doi:10.1097/yic.0000000000000285
   PubMed Web of Science ®Google Scholar
• Dalingwater L. NHS staffing shortages and the Brexit effect. Observatoire de la société britannique. 2019;24:67–86. doi:10.4000/osb.3216
   Google Scholar
• Iacobucci G. Covid-19: NHS trusts declare “critical incidents” because of staff shortages. BMJ. 2022;376:o3. doi:10.1136/bmj.o3
   PubMedGoogle Scholar
• Pappa S, Barnett J, Berges I, Sakkas N. Tired, worried and burned out, but still resilient: a cross-sectional study of mental health workers in the UK during the COVID-19 pandemic. Int J Environ Res Public Health. 2021;18(9):4457. doi:10.3390/ijerph18094457
   PubMed Web of Science ®Google Scholar
• Wallman P, Clark I, Taylor D. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort – a five-year mirror image study. J Psychiatr Res. 2022;148:131–136. doi:10.1016/j.jpsychires.2022.01.044
   PubMed Web of Science ®Google Scholar
• Wallman P, Clark I, Taylor D. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: two year follow-up of use in clinical practice. J Psychopharmacol. 2021;35(9):1091–1098. doi:10.1177/02698811211009794
   PubMed Web of Science ®Google Scholar
• Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3–38. doi:10.1111/j.0065-1591.2000.0ap25.x
   PubMedGoogle Scholar
• Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 2013;150(1):42–50. doi:10.1016/j.schres.2013.07.009
   PubMed Web of Science ®Google Scholar